- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05189886
Transcatheter Aortic Valve Replacement (TAVR) Double Balloon Valvuloplasty
In this study, the investigators evaluate whether routine double inflation of the valve could have a lasting impact. The investigators hypothesize that a routine second reinflation of the balloon, or "double tap", will improve flow across the valve when compared to a single inflation. The investigators hypothesize that "double tap" (1) will decrease mean gradient between first and second inflation during the procedure, (2) will decrease mean gradient on immediate post procedure and 30 day postprocedure echocardiograms when compared to mean gradient gradient after single inflation. Less obstruction indicated by lower mean gradient early after deployment may translate to improved 5 and 10 year outcomes. Furthermore, the investigators hypothesize that this small change in technique will have no effect on procedure time or complications and the change will not result in any increase in perioperative vascular complications, or new permanent pacemaker insertion.
The primary objective of this study is to determine if double valve inflation during a TAVR procedure improves valve area and mean gradients as measured by echocardiogram immediately following the procedure and at 30 days follow up.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Contatto studio
- Nome: Erin Ross
- Numero di telefono: 8059488278
- Email: eross1@cmhshealth.org
Luoghi di studio
-
-
California
-
Ventura, California, Stati Uniti, 93003
- Reclutamento
- Community Memorial Hospital
-
Contatto:
- Erin Ross
- Numero di telefono: 805-948-8278
- Email: eross1@cmhshealth.org
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Male or female ≥18 years of age
- Diagnosis of severe native valve aortic stenosis
- Meets the standard of care indications to undergo TAVR procedure (aortic valve area <1.0 cm2 or mean pressure gradient >40 mmHg or peak velocity >4.0 m/s or aortic valve area index <0.6).
- Provided informed consent.
Exclusion Criteria:
- History of prior aortic valve replacement
- Pre-existing moderate to severe aortic regurgitation
- Lacking pre-procedure echocardiogram
- Patients planning to undergo multiple valve replacements simultaneously
- Intraoperative arrhythmia
- Intraoperative hemodynamic instability
- Intraoperative complication during initial inflation (such as: aortic dissection, coronary artery occlusion, coronary artery dissection)
- At the discretion of the principal investigator, any reason that the potential subject may be unfit for participation, such as frailty.
Piano di studio
Come è strutturato lo studio?
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Prospective
The prospective phase will enroll patients planning to undergo TAVR, at the discretion of Drs.
Wan and Fatemi, and if they meet all of the inclusion criteria and none of the exclusion criteria.
All patients who provide consent will undergo the TAVR procedure where the valve will be double inflated.
Echocardiogram results and procedure details will be collected as data.
At the patient's 30-day follow-up clinic visit, as per standard of care, they will be re-evaluated with an echocardiogram.
Details from that follow-up visit and the echocardiogram results will be collected as data.
Prospective enrollment will begin upon IRB approval and we plan to continue enrollment until December 31, 2023, or once 200 participants are reached, whichever comes first.
|
The prospective phase will enroll patients planning to undergo TAVR, at the discretion of Drs.
Wan and Fatemi, and if they meet all of the inclusion criteria and none of the exclusion criteria.
All patients who provide consent will undergo the TAVR procedure where the valve will be double inflated.
Echocardiogram results and procedure details will be collected as data.
At the patient's 30-day follow-up clinic visit, as per standard of care, they will be re-evaluated with an echocardiogram.
Details from that follow-up visit and the echocardiogram results will be collected as data.
Prospective enrollment will begin upon IRB approval and we plan to continue enrollment until December 31, 2023, or once 200 participants are reached, whichever comes first.
|
|
Retrospective
The retrospective phase will collect data from previous TAVR procedures completed between February 2019 and October 1, 2021.
Data from up to 200 patient charts will be collected using the Society of Thoracic Surgeons/American College of Cardiology that is maintained by the CMH Cardiology Department.
The population will be de-identified as the purpose is to obtain descriptive information from the medical records to utilize for propensity match scoring.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Valve area
Lasso di tempo: Immediately following the procedure
|
Valve area as measured by echocardiogram
|
Immediately following the procedure
|
|
Valve area
Lasso di tempo: At 30 days follow up
|
Valve area as measured by echocardiogram
|
At 30 days follow up
|
|
Mean gradient
Lasso di tempo: Immediately following the procedure
|
Mean gradient as measured by echocardiogram
|
Immediately following the procedure
|
|
Mean gradient
Lasso di tempo: At 30 days follow up
|
Mean gradient as measured by echocardiogram
|
At 30 days follow up
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Jennifer Wan, MD, Community Memorial HealthCenter
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2021-HSR013
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .